

2025/26 RSV Prevention Program

Mississauga Health Primary Care Network

Dr. Hetal Patel, MD, MPH, CCFP, FRCPC
Associate Medical Officer of Health
Region of Peel – Public Health



Land Acknowledgement

We acknowledge that we are gathered today on the traditional territory of the Mississaugas of the Credit, the Anishnabeg, the Chippewa, the Haudenosaunee, and the Wendat peoples, and that this land continues to be home to many diverse First Nations, Inuit, and Métis peoples. We also recognize that Peel Region is covered by Treaty 13 with the Mississaugas of the Credit.

We are grateful to live and work on this land, and we are committed to respecting its history, the rights of Indigenous Peoples, and our ongoing responsibilities to reconciliation.

Disclosure of conflict of interest

No conflicts to declare

Agenda

1. RSV Overview
2. RSV Prevention Program
 - a) Infant and high-risk children
 - b) Pregnancy
 - c) Older adults
3. Ordering RSV products from Peel Public Health
4. Resources and Events

RSV Overview



Respiratory Syncytial Virus (RSV)

- **Seasonality:** November to April (peak in December)
- **Transmission:** respiratory droplets
- **Incubation period:** 2-8 days
- **Period of communicability:** ~8 days (ranges from 1-21 days)
- **Symptoms:** fever, cough, runny nose, fatigue; infants may show irritability, feeding/breathing difficulty, bronchiolitis, pneumonia
- **High risk:** infants, young children and older adults with comorbidities
- **Diagnosis:** usually clinical; hospital cases → nasopharyngeal swab
- **Treatment:** supportive care; most recover in 1-2 weeks; severe cases may need oxygen & hospitalization

[Respiratory syncytial virus \(RSV\): For health professionals - Canada.ca](https://www.canada.ca/en/health-canada/services/respiratory-syncytial-virus-rsv-for-health-professionals.html)

Respiratory Syncytial Virus (RSV)

- **Impact on Infants:**

- 20-30% develop bronchiolitis/pneumonia
- ~2% hospitalized in first year.

- **Impact on older adults:**

- Higher rates of hospitalization, ICU admission, and death.



OVERVIEW

Burden of disease of respiratory syncytial virus in infants, young children and pregnant women and people

Elissa M Abrams^{1,2,3}, Pamela Doyon-Plourde¹, Phaedra Davis^{1,4}, Nicholas Brousseau⁵, Andrea Irwin⁶, Winnie Siu^{1,4}, April Killikelly^{1*}

[ccdrv50i12a01-eng.pdf](#)

RSV prevention program



RSV Immunization Products 2025/26

Product name	Product type	Target population
Beyfortus®	Monoclonal antibody	Newborns and infants <8 months of age during their first RSV season
		High-risk children up to 24 months of age in their second RSV season
Abrysvo™	Bivalent recombinant protein subunit vaccine	Pregnant persons 32-36 weeks of gestation
		High-risk adults 60-74 years of age
		All adults 75 +
Arexvy	Adjuvanted recombinant protein subunit vaccine	High-risk adults 60-74 years of age
		All adults 75 +

Beyfortus[®] - Infants and high-risk children











- Not a vaccine!
- Injectable monoclonal antibody that provides passive immunization
- Replaces Synagis[®] (palivizumab)
- Strong protection in first months of life, efficacy through 5 months and potential full-season coverage
- ↓ 81-83% hospital admission
- Not necessary or recommended if the infant has already had a lab confirmed RSV infection during the current RSV season

Sources: [Respiratory syncytial virus \(RSV\) vaccines: Canadian Immunization Guide - Canada.ca](#)

Beyfortus[®] - Quebec Data 2024/25

- Effectiveness exceeded 80% for all eligible groups.
- Effectiveness against: ER visits (86%) , hospitalization (89%) and ICU admission (88%)
- Number needed to vaccinate
 - 41 at-birth to prevent 1 RSV associated hospitalization
 - 58 catch-up (given to <6 months old) to prevent 1 RSV associated hospitalization



Nirsevimab effectiveness, number needed to immunize and impact on severe RSV outcomes in preterm, high-risk and healthy-term infants, Quebec, Canada

 Sara Carazo,  Manale Ouakki,  Danuta M Skowronski,  Maude Paquette,  Nicholas Brousseau,  Denis Talbot,  Charles-Antoine Guay,  Caroline Quach,  Rodica Gilca,  Jesse Papenburg

doi: <https://doi.org/10.1101/2025.07.27.25332262>

<https://www.medrxiv.org/content/10.1101/2025.07.27.25332262v1>

Beyfortus® uptake 2024/25 - Ontario



Major reason parents who chose not to have their newborn vaccinated in hospital prior to discharge **reported a desire to consult with their primary care provider first**

Beyfortus[®] eligibility

- Administration begins October 1, 2025
- Infants born April 1, 2025 or after **and** less than 8 months of age up to the end of the RSV season.
- High-risk children up to 24 months of age who remain vulnerable from severe RSV disease through their second RSV season.

Beyfortus® eligibility cont.

Children up to 24 months of age who remain vulnerable from severe RSV disease through their second RSV season, with:

- **Chronic lung disease (CLD)**, including bronchopulmonary dysplasia (BPD), defined by need for ongoing respiratory support and supplemental oxygen therapy at 36 weeks postmenstrual age (gestational age at birth plus chronological age) or discharged home, if earlier.
- Hemodynamically significant **cyanotic or acyanotic congenital heart disease (CHD)** defined as infants requiring corrective surgery or are on cardiac medication for congestive heart failure or diagnosed with moderate to severe pulmonary hypertension
- **Severe immunodeficiency**
- **Down Syndrome / Trisomy 21**
- **Cystic fibrosis** with recurrent pulmonary exacerbations requiring hospitalization, deteriorating pulmonary function and/or severe growth delay
- **Neuromuscular disease** impairing clearing of respiratory secretions.
- **Severe congenital airway anomalies** impairing the clearing of respiratory secretions

Beyfortus® Administration guidelines

Category	Weight	Dose
Newborns born during the current RSV season OR Infants born April 1 or after and less than 8 months of age up to the end of the RSV season	< 5 kg	50mg in 0.5mL dose administered IM (100mg/mL syringe)
	≥ 5 kg	100mg in 1mL dose administered IM (100mg/mL syringe)
High-risk children up to 24 months of age in their second RSV season	N/A	200mg (two 1 mL injections administered IM in two separate injection sites) If weight less than 10 kg in second RSV season, 100 mg may be considered at clinical discretion of the HCP.

Refer to [Ministry guidance](#) for children undergoing cardiac surgery with cardiopulmonary bypass

Abrysvo™ - Pregnant individuals

- Bivalent recombinant protein subunit vaccine
- Single dose at 32-36 weeks GA if infant will be born during RSV season and Beyfortus® is not planned.
- Provides passive antibody transfer, protecting infants for up to 6 months.
- Parent may have multi-year protection and there is no recommendation for re-vaccination in future pregnancies
- Dosing: 0.5mL IM
- Administration can begin as soon as supply is available.



Abrysvo™ - Pregnant individuals

- As per the National Advisory Committee on Immunization (NACI), **Beyfortus® is the preferred product to protect infants** over vaccination in pregnancy based on its efficacy, duration of protection, and favourable safety profile
- **Use one approach:** either maternal vaccination *or* infant antibody. Both together not needed.
 - Exceptions:
 - Infants born <14 days after administration of Abrysvo
 - All premature infants born <37 weeks GA
 - Infants who meet any of the prior high-risk criteria

Abrysvo™ and Arexvy - Older adults

- Arexvy is considered the primary product for older adults this season due to supply availability.
- Arexvy is an adjuvanted recombinant protein subunit vaccine
- Administration can begin as soon as supply is available.
- Adults who have previously received a dose of RSV vaccine, do not need to receive another dose this season. Booster doses are not currently recommended.
- Dosing: 0.5mL IM
- May receive vaccination after an RSV infection (no specific interval required)



RSV program – Older Adult

Eligibility

- All individuals 75 years and older - **new for the 2025/26 season**
- Individuals 60 to 74 years of age who are also:
 - resident of a long-term care home, retirement home, elder care lodges or similar settings
 - hospitalized and receiving alternate level of care (ALC) or in a similar setting (e.g., complex continuing care, transitional programs).
 - patients with glomerulonephritis (GN) who are moderately to severely immunocompromised.
 - receiving hemodialysis or peritoneal dialysis.
 - recipients of solid organ or hematopoietic stem cell transplant.
 - experiencing homelessness.
 - identifies as First Nations, Inuit, or Métis.

As per NACI - RSV vaccine may be considered as an individual decision by adults 50-74 years of age with their health care provider (private pay).

Vaccine safety

Common side effects (mild and short-lasting):

- Beyfortus®: Rash, fever, pain, swelling or redness at injection site
- Abrysvo™/Arexvy: Rash, fever, pain, swelling or redness at injection site, nausea, diarrhea, headache, muscle aches

Contraindications and precautions

- Known hypersensitivity or history of severe allergic reaction to any product ingredients.
- Administration should be postponed during severe acute illness (do not delay for minor acute illness with or without fever)

Co-administration

NACI suggests it is acceptable and supported to administer both seasonal and non-seasonal vaccines with RSV.

RSV, Influenza and COVID-19

- Can be administered at the same time

RSV and other recommended vaccines (Shingles, pneumococcal, Tdap)

- Can be administered at the same time

Note: If multiple injections are to be given at the same visit, separate limbs should be used if possible. Alternatively, the injections may be administered into the same muscle separated by at least 2.5 cm (1"). Different immunization equipment (needle and syringe) must be used for each immunization.

Adverse events following immunization (AEFI)

All vaccines

- Complete an [adverse event following immunization reporting form](#) from Public Health Ontario.
- Fax form to Peel Public Health at **905-565-0426**.

Monoclonal antibodies (Beyfortus)

- Report any Beyfortus adverse events to Health Canada, using the [Side Effect Reporting Form](#).
- Fax to 1-866-678-6789

Report of Adverse Event Following Immunization (AEFI)

Public Health Ontario | Santé publique Ontario

When completed, please send the form to your local [Public Health Unit](#) by a secure means. For more information about AEFI reporting in Ontario visit the [Public Health Ontario website](#). The form should be used to capture AEFIs for all vaccinees.

Case ID (for local use only):

1 - CLIENT AND REPORTING SOURCE INFORMATION

Client last name: Ontario Health Card #:

Given name(s): Date of Birth (YYYY-MM-DD):

Sex: ☐ Male ☐ Female ☐ Other ☐ Unknown

Parent/guardian/caregiver full name, as applicable: Telephone #:

Address: City: Postal Code:

Reported to public health by:

Relationship with case:

Form completed by: Date of report (YYYY-MM-DD):

Contact information of reporter (if different from above):

2 - IMMUNIZATION INFORMATION

Date (YYYY-MM-DD)	Time (HH:MM)	Manufacturer / Trade Name	Lot #	Lot exp. Date (YYYY-MM-DD)	Dose #	Site	Route
<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>

SIDE EFFECT REPORTING FORM

Reporting suspected side effects (also known as adverse reactions) to marketed health products in Canada may contribute to the identification of previously unrecognized rare or serious side effects, which may lead to changes in the product's safety information. Companies are encouraged to submit this form and supporting data confidentially to the Health Canada.

226 completed form to 1-866-678-6789
For more information call 1-866-234-2345

A) About the person who had the side effect		B) Suspected health product	
1. Age	2. Sex	3. Weight	4. Height
5. Years	6. Sex	7. Weight	8. Height
9. Medical history and other relevant information (e.g., pregnancy, chronic conditions, etc.)	10. Date	11. Lot #	12. Date
13. Country of residence	14. Where it was purchased/distributed	15. Country of residence	16. Where it was purchased/distributed
17. Country of residence	18. Country of residence	19. Country of residence	20. Country of residence
21. Country of residence	22. Country of residence	23. Country of residence	24. Country of residence
25. Country of residence	26. Country of residence	27. Country of residence	28. Country of residence
29. Country of residence	30. Country of residence	31. Country of residence	32. Country of residence
33. Country of residence	34. Country of residence	35. Country of residence	36. Country of residence
37. Country of residence	38. Country of residence	39. Country of residence	40. Country of residence
41. Country of residence	42. Country of residence	43. Country of residence	44. Country of residence
45. Country of residence	46. Country of residence	47. Country of residence	48. Country of residence
49. Country of residence	50. Country of residence	51. Country of residence	52. Country of residence
53. Country of residence	54. Country of residence	55. Country of residence	56. Country of residence
57. Country of residence	58. Country of residence	59. Country of residence	60. Country of residence
61. Country of residence	62. Country of residence	63. Country of residence	64. Country of residence
65. Country of residence	66. Country of residence	67. Country of residence	68. Country of residence
69. Country of residence	70. Country of residence	71. Country of residence	72. Country of residence
73. Country of residence	74. Country of residence	75. Country of residence	76. Country of residence
77. Country of residence	78. Country of residence	79. Country of residence	80. Country of residence
81. Country of residence	82. Country of residence	83. Country of residence	84. Country of residence
85. Country of residence	86. Country of residence	87. Country of residence	88. Country of residence
89. Country of residence	90. Country of residence	91. Country of residence	92. Country of residence
93. Country of residence	94. Country of residence	95. Country of residence	96. Country of residence
97. Country of residence	98. Country of residence	99. Country of residence	100. Country of residence

© 2014 Health Canada. All rights reserved.

Form 226-100-01 / 1000-01-01

Canada

Adverse events following immunization (AEFI)

- Some common or mild events do not need to be reported. These include:
 - Fever that is not accompanied by any other symptoms
 - Injection site reactions that last <4 days and does not extend past the nearest joint
 - Vasovagal syncope (without injury)
 - Events that are clearly attributable to other causes

RSV Immunization Delivery

Product	Population	Delivery setting
Beyfortus®	In-season births	Hospital (prior to discharge)
	Out-of-season infants/births outside hospital	Primary care provider
	Second RSV season	Primary care provider
Arexvy/Abrysvo™	High risk 60-74 years, 75+, pregnancy	Primary care provider Obstetrician/midwife

Note: Pharmacies are not providing publicly funded RSV vaccines this year. However, they can administer non-publicly funded RSV vaccines (e.g. adults aged 50+ that do not meet eligibility criteria)

Ordering RSV Products



Distribution timeline

Timing	Order/distribution
September 18	Pre-ordering opened for hospitals, LTCH/RH, family health teams, pediatrician offices
Week of September 29th	Delivery of respiratory vaccines from Ministry to PHU
Week of October 6th	Begin delivery of vaccines to high-risk settings Ordering for other providers opens on Peel Health Professionals Portal
Week of October 27th	All initial orders to be delivered to all providers in Peel

NOTE: These timelines are based on the assumption that Peel Public Health receives the respiratory vaccines on time from the Ministry of Health

Ordering and Distribution Plan

- Respiratory vaccines are distributed via free delivery
- Deliveries occur between 9am-4pm and a receiver is required at the clinic; email notice will be sent the day before
- Order limits for respiratory vaccines have been applied
- Order based on fridge capacity as package sizes may be larger due to single-dose
- Do not order enough vaccines for the season. Order a one month supply.

Ordering vaccines

<https://www.peelregion.ca/health/professionals/vaccines/ordering/>



[Home](#) > [Business and professionals](#) > [Health professionals](#) > [Vaccines for health professionals](#)

Vaccine ordering

Order routine, influenza, RSV, COVID-19, and high risk vaccines.

HB, HPV-9, and Men-C-ACYW vaccine ordering update

Peel physicians can now order HB and HPV-9, and Men-C-ACYW vaccines through the [Health Professional Portal](#) for:

- Students up to Grade 12 who missed their Grade 7 school-based doses.
- Eligible individuals under high-risk programs (HB and HPV-9 only).

Faxed or emailed high-risk requests for HB and HPV-9 will no longer be required.

Vaccines that can be ordered through the Health Professionals Portal:

- Routine vaccines
- Influenza
- COVID-19
- RSV
- HB (under the high-risk programs)
- HPV-9 (under the high-risk programs)
- School-based vaccines (HB, HPV-9, Men-C-ACYW)

[Order vaccines](#)

Related information:

- [Register if you do not have an account](#)
- [Help with our new vaccine ordering process](#)

Vaccine availability for the respiratory illness season is communicated through [Health Professionals Updates](#).

Hepatitis A and Meningococcal high-risk vaccine programs

To order additional vaccines under high-risk programs, fill out the appropriate requisition form and fax to the number indicated on the form:

- [Hepatitis A vaccine requisition](#)
- [Meningococcal vaccine requisition](#)



To access this page, you have to log in to Peel Health Professionals Portal.

Username

Log In

For order support contact: vaccinemanagement@peelregion.ca

RSV Prevention Program

- Primary Care Role

- Counselling pregnant patients on infant immunization with Beyfortus[®] prior to discharge from hospital
- Administration of Beyfortus[®] to eligible patients
- Administration of Abrysvo[™] to pregnant individuals
- Administration of Abrysvo[™] or Arexvy to eligible older adults.

Billing (OMA)

- Use OHIP fee code G538 (other immunizing agents).
- G538 is an "in-basket" service for physicians in a family health organization (FHO) and family health network (FHN) physicians.
- G538 includes the provision of routine information and counselling related to immunizations.

[RSV immunization program | OMA](#)

Service	Fee code
Sole purpose of visit	G700 (basic fee) + G538 (other immunizing agents)
With assessment (for an issue unrelated to RSV)	Appropriate assessment fee code (for example, A007 for intermediate assessment or well baby care) + G538 (other immunizing agents)
With newborn care	Appropriate assessment fee code, e.g., H001/H261 (newborn care in hospital and/or home) + G538 (other immunizing agents)
With counselling (20+ minutes)	Appropriate individual counselling code (e.g., K013) + G538 (other immunizing agents)

Resources & Events



Resources

[Updated PCMCH Resources on RSV Prevention for Infants and High-Risk Children - PCMCH-](#)

Fact sheets available in multiple languages
QR code poster available for your office

Protecting Your Child from RSV

FACT SHEETS AVAILABLE IN MULTIPLE LANGUAGES



Respiratory syncytial virus (RSV) causes an illness that affects the airway and lungs, especially in babies and young children.

Learn about RSV and how to protect your child by scanning the QR code for your language and reading the fact sheet.



English



French
(Français)



Simplified Chinese
(简体中文)



Traditional Chinese
(繁體中文)



Arabic
(العربية)



Italian
(Italiano)



Punjabi
(ਪੰਜਾਬੀ)



Spanish
(Español)



Read the fact sheet for Indigenous parents, families and caregivers. Available in English, French, Cree, Inuktitut, Ojibway and Mohawk.



For more information,
visit pcmch.on.ca/RSV



Resources

Ministry of Health - Vaccines

- [Respiratory Syncytial Virus \(RSV\) prevention programs - HCP](#)

National Advisory Committee on Immunization

- [Statement on the prevention of respiratory syncytial virus disease in infants](#)
- [Statement on the prevention of respiratory syncytial virus disease in older adults](#)

Canadian Immunization Guide

- [Respiratory syncytial virus \(RSV\) vaccines chapter](#)

Health Professional Updates

- [Health Professionals Updates - peelregion.ca](#)

Upcoming Peel Respiratory Immunization Webinar



Respiratory Immunization Update 2025/26

Details

Peel Public Health invites physicians and community health care providers to a webinar on **RSV, COVID-19, and Influenza Immunization**. Learn about the latest respiratory illness trends and immunization recommendations to support your practice and protect patients this season.

This webinar will be hosted by Dr. Hetal Patel, an Associate Medical Officer of Health at Peel Public Health. Dr. Patel's portfolio includes supporting the Immunization Services Division and the Physician Outreach program. She also practices family medicine part-time.

Details

- Wed, Oct 08
- 6:00 PM - 7:00 PM EDT
- Online event

[Register](#)

Peel Public Health invites physicians and community health care providers to a webinar on **RSV, COVID-19, and Influenza Immunization**. Learn about the latest respiratory illness trends and immunization recommendations to support your practice and protect patients this season.

Session name: **Respiratory Immunization Update 2025/26**

Date: **October 8, 2025**

Time: **6:00 to 7:00 p.m.**

Where: Virtual event (**Microsoft Teams**)

[Registration link](#)

Peel Public Health Clinics

- RSV for individuals 75+ without primary care provider.
- COVID-19 and Influenza for children 6 months – 4 years.

Limited clinics (October – November)

Appointment required, no walk-ins.

[Vaccinations - peelregion.ca](https://www.peelregion.ca/vaccinations/) will be updated with appointment booking information.

Peel Public Health will not be offering Beyfortus® for infants or RSV vaccination to pregnant individuals. A list of providers accepting unattached patients will be listed on [Respiratory syncytial virus - peelregion.ca](https://www.peelregion.ca/respiratory-syncytial-virus/).

Sign up for Health Professionals Updates (HPU's)

Peel Public Health

Information for health professionals



To find out about vaccines, communicable diseases, infection prevention and control, and other resources, visit:

peelregion.ca/HealthPros

Subscribe to Health Professionals Updates

Receive emails with new or updated public health information relevant to physicians in Peel.

[Sign up](#)

 Peel Region

Search...



[Home](#) > [Business and professionals](#) > [Health professionals](#)

Health Professionals Updates

Sharing important information with Peel physicians.

Peel Public Health uses Health Professionals Updates to share new or updated public health information relevant to physician practice in the community.

Health care providers searching for access to an archived link or document from a Health Professionals Update can [contact us](#).

September 2025

[September 9, 2025, Vol. 18, No. 23](#)

- Immunization screening letters for the 2025-2026 school year.
- Reminder: Updated Polio vaccine guidance for children with OPV history.

[September 3, 2025, Vol. 18, No. 22](#)

Update: Additional vaccines now available for ordering on the Health Professionals Portal.

[August 2025](#)



[July 2025](#)



[June 2025](#)



General immunization questions

Region of Peel, Public Health 905-799-7700

8:30am – 4:30pm M-F.

For order support contact: vaccinemanagement@peelregion.ca



Questions

